Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Aug;52(2):245–249. doi: 10.1038/bjc.1985.184

Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin.

A Bennett, M A Carroll, P B Melhuish, I F Stamford
PMCID: PMC1977112  PMID: 4027166

Abstract

WHT/Ht mice transplanted s.c. with NC carcinoma were treated with 16,16-dimethyl prostaglandin E2 methyl ester (di-me-PGE2) and/or indomethacin. Each primary tumour was excised under anaesthesia 3 weeks after transplantation, weighed and extracted for prostaglandins. Mouse survival time and tumour recurrence were measured. Di-me-PGE2 10 micrograms, injected at the tumour site on alternate days from day 1 to 19, indomethacin 2.5 mg kg-1 daily by mouth, or both drugs together resulted in lighter tumours (respectively 45, 45 and 52% less, n = 18 to 20 per group, P less than 0.02) compared with vehicle-treated controls. Indomethacin reduced the tumour prostaglandin yield, but the biological activity in extracts of tumours from mice given di-me-PGE2 was high. The median survival time was longer in mice receiving indomethacin alone (61 days from tumour transplantation compared with 50 days in controls P less than 0.02). Di-me-PGE2 alone had little or no effect on survival (median 48 days) but counteracted the increase with indomethacin (di-me-PGE2 + indomethacin, 49 days median survival). There were no obvious effects of the treatments on tumour recurrence at the excision site, but there was a higher incidence of involved lymph nodes in mice given di-me-PGE2.

Full text

PDF
245

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett A., Berstock D. A., Carroll M. A. Increased survival of cancer-bearing mice treated with inhibitors of prostaglandin synthesis alone or with chemotherapy. Br J Cancer. 1982 May;45(5):762–768. doi: 10.1038/bjc.1982.118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bennett A., Houghton J., Leaper D. J., Stamford I. F. Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prostaglandins. 1979 Feb;17(2):179–191. doi: 10.1016/0090-6980(79)90037-6. [DOI] [PubMed] [Google Scholar]
  3. Bennett A., Stamford I. F., Unger W. G. Prostaglandin E2 and gastric acid secretion in man. J Physiol. 1973 Mar;229(2):349–360. doi: 10.1113/jphysiol.1973.sp010142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Favalli C., Garaci E., Etheredge E., Santoro M. G., Jaffe B. M. Influence of PGE on the immune response in melanoma-bearing mice. J Immunol. 1980 Aug;125(2):897–902. [PubMed] [Google Scholar]
  5. Favalli C., Garaci E., Santoro M. G., Santucci L., Jaffe B. M. The effect of PGA1 on the immune response in B-16 melanoma-bearing mice. Prostaglandins. 1980 Apr;19(4):587–594. doi: 10.1016/s0090-6980(80)80008-6. [DOI] [PubMed] [Google Scholar]
  6. Fitzpatrick F. A., Stringfellow D. A. Prostaglandin D2 formation by malignant melanoma cells correlates inversely with cellular metastatic potential. Proc Natl Acad Sci U S A. 1979 Apr;76(4):1765–1769. doi: 10.1073/pnas.76.4.1765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Flower R. J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974 Mar;26(1):33–67. [PubMed] [Google Scholar]
  8. Hewitt H. B., Blake E. R., Walder A. S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 1976 Mar;33(3):241–259. doi: 10.1038/bjc.1976.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hial V., Horakova Z., Shaff F. E., Beaven M. A. Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Eur J Pharmacol. 1976 Jun;37(2):367–376. doi: 10.1016/0014-2999(76)90044-3. [DOI] [PubMed] [Google Scholar]
  10. Hofer D., Dubitsky A. M., Reïlly P., Santoro M. G., Jaffe B. M. The interactions between indomethacin and cytotoxic drugs in mice bearing B-16 melanomas. Prostaglandins. 1980 Dec;20(6):1033–1038. doi: 10.1016/0090-6980(80)90057-x. [DOI] [PubMed] [Google Scholar]
  11. Honn K. V., Cicone B., Skoff A. Prostacyclin: a potent antimetastatic agent. Science. 1981 Jun 12;212(4500):1270–1272. doi: 10.1126/science.7015512. [DOI] [PubMed] [Google Scholar]
  12. Honn K. V., Dunn J. R., 2nd, Morgan L. R., Bienkowski M., Marnett L. J. Inhibition of DNA synthesis in Harding-Passey melanoma cells by prostaglandins A1 and A2: comparison with chemotherapeutic agents. Biochem Biophys Res Commun. 1979 Apr 13;87(3):795–801. doi: 10.1016/0006-291x(79)92028-x. [DOI] [PubMed] [Google Scholar]
  13. Jubiz W., Frailey J., Smith J. B. Inhibitory effect of prostaglandin F2 alpha on the growth of a hormone-dependent rat mammary tumor. Cancer Res. 1979 Mar;39(3):998–1000. [PubMed] [Google Scholar]
  14. Lee E. T., Desu M. M. A computer program for comparing K samples with right-censored data. Comput Programs Biomed. 1972 Nov;2(4):315–321. doi: 10.1016/0010-468x(72)90019-0. [DOI] [PubMed] [Google Scholar]
  15. Lynch N. R., Castes M., Astoin M., Salomon J. C. Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br J Cancer. 1978 Oct;38(4):503–512. doi: 10.1038/bjc.1978.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lynch N. R., Salomon J. C. Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J Natl Cancer Inst. 1979 Jan;62(1):117–121. [PubMed] [Google Scholar]
  17. Sakai T., Yamaguchi N., Shiroko Y., Sekiguchi M., Fujii G., Nishino H. Prostaglandin D2 inhibits the proliferation of human malignant tumor cells. Prostaglandins. 1984 Jan;27(1):17–26. doi: 10.1016/0090-6980(84)90217-x. [DOI] [PubMed] [Google Scholar]
  18. Santoro M. G., Jaffe B. M. Inhibition of Friend erythroleukaemia-cell tumours in vivo by a synthetic analogue of prostaglandin E2. Br J Cancer. 1979 Apr;39(4):408–413. doi: 10.1038/bjc.1979.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Santoro M. G., Philpott G. W., Jaffe B. M. Inhibition of B-16 melanoma growth in vivo by a synthetic analog of prostaglandin E2. Cancer Res. 1977 Oct;37(10):3774–3779. [PubMed] [Google Scholar]
  20. Santoro M. G., Philpott G. W., Jaffe B. M. Inhibition of tumour growth in vivo and in vitro by prostaglandin E. Nature. 1976 Oct 28;263(5580):777–779. doi: 10.1038/263777a0. [DOI] [PubMed] [Google Scholar]
  21. Trevisani A., Ferretti E., Capuzzo A., Tomasi V. Elevated levels of prostaglandin E2 in Yoshida hepatoma and the inhibition of tumour growth by non-steroidal anti-inflammatory drugs. Br J Cancer. 1980 Mar;41(3):341–347. doi: 10.1038/bjc.1980.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Unger W. G., Stamford I. F., Bennett A. Extraction of prostaglandins from human blood. Nature. 1971 Oct 1;233(5318):336–337. doi: 10.1038/233336b0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES